United Nations Moving Ahead On Consolidation of AIDS Programs

The program, called the Joint and Co-Sponsored U.N. Program on HIV/AIDS, was first proposed by the World Health Organization's (WHO) executive board of directors in January of this year. It was given final approval by the U.N. Economic and Social Council last month. Expected to be fully functional by January 1996, the program would link AIDS-related activities of six participating organizations: WHO; the World Bank; the U.N. Educati

Written byNeeraja Sankaran
| 4 min read

Register for free to listen to this article
Listen with Speechify
0:00
4:00
Share

The program, called the Joint and Co-Sponsored U.N. Program on HIV/AIDS, was first proposed by the World Health Organization's (WHO) executive board of directors in January of this year. It was given final approval by the U.N. Economic and Social Council last month. Expected to be fully functional by January 1996, the program would link AIDS-related activities of six participating organizations: WHO; the World Bank; the U.N. Educational, Scientific, and Cultural Organization (UNESCO); the U.N. Development Program (UNDP); the U.N. International Children's Emergency Fund (UNICEF); and the U.N. Fund for Population (UNFP). Researchers and others involved in the consolidation envision the program as a central resource to which members of the six participating organizations can turn for funding and guidance in both policy and scientific research.

"What this [program] means is that the results from the research can be more readily and immediately applied where they are urgently needed," says ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies